Inclusion Criteria:~* Part 1: Participants who completed the open-label extensions (OLEs) of studies WN25203 or
WN28745 will be eligible to participate in Part 1 of the study~* Part 2: All participants who have completed
Week 104 visit in Part 1 will be eligible for Part 2 of the study~* For Part 1 and Part 2:~* For women of
childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at
least 16 weeks after the last dose of study drug~* Agreement to not donate blood or blood products for
transfusion for the duration of the study and for 1 year after final dose of study drug~* Availability of a
person ('caregiver') who in the investigator's judgement, has frequent and sufficient contact with the
participant~
